



**FINAL**  
**ASX / Media Release**  
**4 May 2015**

## **Director Resignation**

**SYDNEY, 4<sup>th</sup> May, 2015: OncoSil Medical Limited (ASX: OSL) (OncoSil Medical, the Company)** advises that Independent Non-executive Director Mr Lawrence Gozlan has decided to step down from the board of OncoSil Medical, effective from today.

Mr Gozlan has taken the decision in order for him to concentrate his focus more clearly on his considerable other business interests.

He has made a significant contribution to the progress of the Company and the development of its clinical programs since joining the board in February 2014. His investment market and corporate advisory experience and expertise in the life sciences sector has been invaluable to OncoSil Medical.

The Company takes this opportunity to thank Mr Gozlan for his considerable input and contribution to the growth of OncoSil Medical to date, and wishes him all the best in his future endeavours.

OncoSil Medical Chairman Dr Roger Aston said:

*"Lawrence has been a key member of the OncoSil Medical team. His drive and enthusiasm along with his undoubted knowledge and understanding of the listed life sciences space has been of major benefit to the Company. He has a growing portfolio of business interests which require his commitment and time, and we acknowledge his decision to step down in order to focus on these interests."*

ENDS

Contact:

**Mr Daniel Kenny**  
**Chief Executive Officer and Managing Director**

E: [daniel.kenny@oncosil.com.au](mailto:daniel.kenny@oncosil.com.au)

T: +61 2 9223 3344

**James Moses**  
**Mandate Corporate**

E: [james@mandatecorporate.com.au](mailto:james@mandatecorporate.com.au)

M: +61 420 991 574

T: +61 2 8211 0612

**About OncoSil Medical Ltd**

OncoSil Medical Ltd (OncoSil Medical) is a clinical-stage Australian Lifesciences company focused on providing new technologies for safer medical radiation treatments. OncoSil Medical's lead product is OncoSil™ with the first target indication being pancreatic & hepatocellular cancer. OncoSil™ is a silicon and P32 (phosphorus) pure beta emitter with the potential to be used medically as a brachytherapy treatment. The OncoSil™ device delivers more concentrated and localised beta radiation compared to external beam radiation. OncoSil Medical has previously conducted four clinical trials with encouraging results on tolerability, safety and efficacy. There is also potential use for OncoSil™ in other solid tumours outside of pancreatic and hepatocellular cancer. FDA and CE Mark approval for pancreatic cancer is the core focus of OncoSil Medical.

**Pancreatic Cancer**

Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2012 338,000 people globally were diagnosed with pancreatic cancer including 43,140 Americans, 70,000 Europeans and 2,546 in Australia. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 5%. The world-wide market for pancreatic drugs is projected by Global Industry Analysis to exceed US\$1.2bn in 2015.

**Hepatocellular carcinoma liver cancer**

Hepatocellular carcinoma (HCC) is the 6<sup>th</sup> most common cancer in the world and afflicts almost a million patients annually. The poor prognosis makes HCC the third leading cause of cancer related mortality, responsible for approximately 600,000 deaths annually. HCC may be cured by surgery or transplantation. The vast majority of patients with HCC have disease which is too advanced for surgical intervention and as a consequence survival ranges from a few months to two or more years, depending on the liver function at diagnosis and the extent of tumour invasion. The value of the HCC market is expected to triple in size to \$1.4b by 2019.